ClinicalTrials.gg
RecruitingNCT07316270Updated Aug 7, 2026

SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)

An interventional study of Catheter Ablation and Usual Care in AF - Atrial Fibrillation and Intracranial Hemorrhage, Spontaneous, sponsored by Beijing Anzhen Hospital. Recruiting at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Beijing Anzhen Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
646
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital — 25 open to participants now, 26 under way, 1 of them phase 3. Atrial Fibrillation · Beijing Anzhen Hospital.

Planned enrollment
9th of 24
646 · median 410
Started
2026
with 10 others
No phase
21 of 36
15 open now
Primary completion
2030-01
later than 17 of 25 live
Registered
26th of 36
by date

Among the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, this one is the 9th largest by planned enrollment of the 24 interventional ones that give a count, is one of 11 that started in 2026, is one of 21 with no phase, reaches primary completion later than 17 of the 25 other live ones, and was the 26th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

25 of the 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital are open now, in 1 country. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Atrial Fibrillation by Beijing Anzhen Hospital, or all of them as a file.
02

Study summary

SAFER-AF is an investigator-initiated, multicenter, open-label, parallel-group trial comparing catheter ablation versus usual care in patients with atrial fibrillation and intracranial hemorrhage.

Read the detailed description

Atrial fibrillation (AF) increases the risk of stroke, heart failure, and mortality. Oral anticoagulation is the standard treatment for preventing thromboembolism, but it also raises the risk of bleeding. About 20-25% of patients with intracranial hemorrhage have AF. Previous randomized trials indicate that restarting anticoagulation may prevent ischemic stroke, but increase risk of recurrent intracranial hemorrhage. Catheter ablation is the first-line rhythm control strategy that reduce thromboembolic risk by maintaining sinus rhythm and potentially reducing the need for long-term anticoagulation. Pulsed field ablation (PFA) uses electroporation to ablate the myocardium by electroporation with high tissue specificity and may shorten the required anticoagulation period.

The SAFER-AF trial is a prospective, multicenter, open-label randomized controlled trial enrolling 646 AF patients with previous spontaneous intracranial hemorrhage, investigating whether catheter ablation provides superior long-term net clinical benefit compared with usual care. Participants will be randomized 1:1 to catheter ablation versus usual care, with a minimum follow-up of 2 years. Patients in catheter ablation group will undergo PFA, followed by low-dose direct oral anticoagulants for 1 month. The primary endpoint is the composite of all-cause mortality, all-cause stroke (ischemic or hemorrhagic), and systemic embolism. SAFER-AF aims to define a safer, individualized therapeutic pathway balancing ischemic protection and hemorrhagic risk, ultimately improving survival and long-term outcomes for AF patients with intracranial hemorrhage.

03

Conditions studied

  • AF - Atrial Fibrillation
  • Intracranial Hemorrhage, Spontaneous
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Between 14 Days and 12 Months After Spontaneous Intracranial Hemorrhage (intraparenchymal or intraventricular hemorrhage, and subdural hematoma)
  3. Able to Access Intracranial Hemorrhage Imaging Data
  4. indicating the presence of atrial fibrillation
  5. CHA₂DS₂-VA Score ≥ 2
  6. Willing to undergo randomization and able to complete follow-up as required

Exclusion criteria

Exclusion Criteria:

  1. Atrial fibrillation secondary to clearly reversible causes (e.g., hyperthyroidism, hypokalemia, etc.)
  2. Fully dependent (modified Rankin Scale [mRS] score > 4)
  3. Uncontrolled hypertension (systolic blood pressure > 160 mmHg)
  4. Presence of uncontrolled active bleeding
  5. Presence of active infection requiring antibiotic treatment
  6. End-stage renal failure or receiving dialysis treatment
  7. Presence of liver failure
  8. Untreated coronary artery disease with indication for revascularization
  9. Presence of intracardiac masses, thrombi, etc., as evaluated by transthoracic echocardiography or transesophageal echocardiography
  10. Expected \< 1 year (e.g., advanced malignant tumors, etc.)
  11. Pregnant, lactating, or women planning to become pregnant
  12. Presence of psychological or psychiatric disorders that prevent understanding or cooperation with the study
  13. Other conditions deemed unsuitable for participation in the study by the investigators
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
646 participants (estimated)

Study arms

  • Active comparator
    Usual care Group

    Drug: Usual Care

  • Experimental
    Catheter Ablation Group

    Procedure: Catheter Ablation

Interventions

  • ProcedureCatheter Ablation

    For patients in the catheter ablation group, low-dose anticoagulation for 1 month after pulsed field ablation is recommended. Suggested regimens include rivaroxaban 10-15 mg once daily, dabigatran 110 mg twice daily, or edoxaban 30 mg once daily. For patients with paroxysmal atrial fibrillation (AF), an ablation strategy based on bilateral pulmonary vein isolation (PVI) is adopted. For patients with persistent AF, PVI plus ethanol infusion of the vein of Marshall and linear ablation (mitral isthmus, cavotricuspid isthmus, and left atrial roof) strategy is recommended. Other additional ablation strategies are determined by the operator.

  • DrugUsual Care

    Patients received standard medical therapy without anticoagulation.

06

What researchers measure

Primary outcomes

  1. Composite of All-Cause Mortality, All-Cause Stroke, and Systemic Embolism

    Time frame: 48 months

Secondary outcomes

  1. Stroke and Systemic Embolism

    Time frame: 48 months

  2. Cardiovascular death

    Time frame: 48 months

  3. Ischemic Stroke

    Time frame: 48 months

  4. Intracranial Hemorrhage

    Time frame: 48 months

  5. ISTH Major Bleeding

    Time frame: 48 months

  6. Clinically relevant non-major bleeding

    Time frame: 48 months

  7. Change in health-related quality of life assessed by the EQ-5D-5L questionnaire

    The EQ-5D-5L (EuroQol five-dimension, five-level) questionnaire is a standardized, generic measure of health-related quality of life. It consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each with five levels of severity. Health states are converted into a single index value using a country-specific value set, with higher index values indicating better health-related quality of life.

    Time frame: 48 months

  8. Change in cognitive function assessed by the Mini-Mental State Examination (MMSE)

    The Mini-Mental State Examination is a 30-point questionnaire used to assess global cognitive function. Scores range from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: 48 months

  9. modified Rankin Scale score

    The modified Rankin Scale (mRS) is a widely used tool for assessing functional disability and dependence in patients with stroke or other neurological disorders. Scores range from 0 to 6, with 0 indicating no symptoms, 5 indicating severe disability requiring constant care, and 6 indicating death. A higher score represents a poorer functional outcome.

    Time frame: 48 months

07

Study locations

2 of 7 sites recruiting
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
    Not yet recruiting
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, Beijing Municipality 100029, China
    Recruiting
    • Liu HE, MD · Contacttheliu@139.com · +86 13810720787
    • Caihua Sang, MD · Contactsch9613070@sina.com · +86 010-81992281
    • Changsheng Ma, MD · Principal investigator
    • Caihua Sang, MD · Principal investigator
  • Xiamen Cadiovascular Hospital
    Xiamen, Fujian, China
    Recruiting
    • Yan Wang · Contactwy@medmail.com.cn · +86-0592-968120
    • Yan Wang, MD · Principal investigator
  • The First Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
    Not yet recruiting
    • Yue Li · Contactly99ly@vip.163.com · +86 13945057313
    • Yue Li, MD · Principal investigator
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang, China
    Not yet recruiting
    • Bo Yu · Contactyubodr@163.coms · +86-0451-86605084
    • Bo Yu, MD · Principal investigator
  • The First Hospital of Jilin University
    Changchun, Jilin, China
    Not yet recruiting
    • Qian Tong · Contacttongqian@jlu.edu.cn · +86-0431-81879801
    • Qian Tong, MD · Principal investigator
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi, China
    Not yet recruiting
    • Zuyi Yuan · Contactyue.wu@xjtu.edu.cn · +86-029-85323473
    • Zuyi Yuan, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jan 2030, 44 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 44 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2025
First posted
Jan 5, 2026
StartActual
May 6, 2026
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07316270
Responsible party
Sponsor
First posted
Jan 5, 2026
Start date
May 6, 2026
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Aug 7, 2026

Study contacts

Liu He
Contact
theliu@139.com
13810720787
Yan Wang
principal investigator · Xiamen Cardiovascular Hospital, Xiamen University
Caihua Sang
principal investigator · Beijing Anzhen Hospital
Changsheng Ma
principal investigator · Beijing Anzhen Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion